Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chubb
UBS
Deloitte
QuintilesIMS
Farmers Insurance
Chinese Patent Office
Johnson and Johnson
Baxter

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,825,137

« Back to Dashboard

Which drugs does patent 7,825,137 protect, and when does it expire?

Patent 7,825,137 protects XALKORI and is included in one NDA.

This patent has twenty-four patent family members in twenty-two countries.
Summary for Patent: 7,825,137
Title:Method of treating abnormal cell growth
Abstract: The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-py- razol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer.
Inventor(s): Christensen; James Gail (San Diego, CA), Zou; Yahong (San Diego, CA)
Assignee: Pfizer Inc. (New York, NY)
Application Number:12/095,114
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,825,137

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-001 Aug 26, 2011 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK) ➤ Try a Free Trial
Pf Prism Cv XALKORI crizotinib CAPSULE;ORAL 202570-002 Aug 26, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,825,137

PCT Information
PCT FiledNovember 23, 2006PCT Application Number:PCT/IB2006/003397
PCT Publication Date:June 14, 2007PCT Publication Number: WO2007/066187

International Family Members for US Patent 7,825,137

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 056832 ➤ Try a Free Trial
Argentina 099982 ➤ Try a Free Trial
Austria 488237 ➤ Try a Free Trial
Australia 2006323027 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
US Department of Justice
Boehringer Ingelheim
Argus Health
Express Scripts
Cipla
Queensland Health
AstraZeneca
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.